Original Article
Cyclophosphamide versus Placebo in Scleroderma Lung Disease
N Engl J Med 2006; 354:2655-2666June 22, 2006
- Abstract
Background
We conducted a double-blind, randomized, placebo-controlled trial to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidence of active alveolitis and scleroderma-related interstitial lung disease.
Methods
At 13 clinical centers throughout the United States, we enrolled 158 patients with scleroderma, restrictive lung physiology, dyspnea, and evidence of inflammatory interstitial lung disease on examination of bronchoalveolar-lavage fluid, thoracic high-resolution computed tomography, or both. Patients received oral cyclophosphamide (≤2 mg per kilogram of body weight per day) or matching placebo for one year and were followed for an additional year. Pulmonary function was assessed every three months during the first year, and the primary end point was the forced vital capacity (FVC, expressed as a percentage of the predicted value) at 12 months, after adjustment for the baseline FVC.
Results
Of 158 patients, 145 completed at least six months of treatment and were included in the analysis. The mean absolute difference in adjusted 12-month FVC percent predicted between the cyclophosphamide and placebo groups was 2.53 percent (95 percent confidence interval, 0.28 to 4.79 percent), favoring cyclophosphamide (P<0.03). There were also treatment-related differences in physiological and symptom outcomes, and the difference in FVC was maintained at 24 months. There was a greater frequency of adverse events in the cyclophosphamide group, but the difference between the two groups in the number of serious adverse events was not significant.
Conclusions
One year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life. The effects on lung function were maintained through the 24 months of the study.
Media in This Article
Figure 1
Screening, Enrollment, and Outcomes.Figure 2
The Percentage of Predicted FVC at 12 Months and Changes in the Percentage of Predicted FVC from Baseline to 12 Months.Article Activity
- Article
Scleroderma (also called systemic sclerosis) is an autoimmune connective-tissue disorder that is characterized by microvascular injury, excessive fibrosis of the skin, and distinctive visceral changes that can involve the lungs, heart, kidneys, and gastrointestinal tract. Forty percent of patients with scleroderma have ventilatory restriction, mainly as a result of interstitial lung disease. Together with pulmonary hypertension, ventilatory restriction has emerged as the leading cause of death related to scleroderma.1,2 The mortality rate among patients with severe ventilatory restriction (as reflected by a forced vital capacity [FVC] that is less than 50 percent of the predicted value) from scleroderma-related interstitial lung disease is approximately 42 percent within 10 years after the onset of the disease (as determined by the patient's recall of the first symptom of scleroderma other than Raynaud's phenomenon),1 an estimate that underscores the need for treatment of this disorder.
A number of agents have been evaluated as treatments for scleroderma-related interstitial lung disease, but none have been proven effective.3 Only cyclophosphamide has shown promise in several retrospective studies, which suggested that it may slow the decrease in or even improve the FVC over time.2-11 Although these results have encouraged many physicians to adopt cyclophosphamide as a standard of care for patients with this disease, the lack of a randomized, prospective study makes it difficult to draw solid conclusions regarding the efficacy, toxicity, and risk–benefit ratio of this drug.
The Scleroderma Lung Study, a 13-center, double-blind, randomized, placebo-controlled trial sponsored by the National Institutes of Health, was designed to evaluate the effectiveness and safety of oral cyclophosphamide for one year in patients with active, symptomatic scleroderma-related interstitial lung disease who were followed for a total of two years. Results from the study indicate that cyclophosphamide has disease-modifying effects on pulmonary function and such measures of response as dyspnea, the health-related quality of life, functional ability, and skin thickness.
Methods
Subjects
Between September 2000 and January 2004, we enrolled patients with limited or diffuse systemic scleroderma12,13 if they had evidence of active alveolitis on examination of bronchoalveolar-lavage (BAL) fluid (defined as neutrophilia of ≥3 percent, eosinophilia of ≥2 percent, or both)2,14 or on thoracic high-resolution computed tomography (CT), any ground-glass opacity, the onset of the first symptom of scleroderma other than Raynaud's phenomenon within the previous seven years, an FVC between 45 and 85 percent of the predicted value,15 and grade 2 exertional dyspnea according to the baseline instrument of the Mahler Dyspnea Index (as measured with the use of the magnitude-of-task component).16 Primary exclusion criteria included a single-breath carbon monoxide diffusing capacity (DlCO) that was less than 30 percent of the predicted value,17 a history of smoking within the preceding six months, other clinically significant pulmonary abnormalities, or clinically significant pulmonary hypertension requiring drug therapy. Patients taking prednisone at a dose of more than 10 mg per day, those who had previously been treated for more than four weeks with oral cyclophosphamide or had received two or more intravenous doses, and those who had recently received other potentially disease-modifying medications were also excluded. The inclusion and exclusion criteria are described in detail in Supplementary Appendix 1 (available with the full text of this article at www.nejm.org). All patients provided written informed consent, and the study was approved by the medical institutional review board at each clinical center.
Screening and Randomization
Patients were screened at each center as outlined in Supplementary Appendix 2, and their eligibility was determined centrally at the data coordinating center at the University of California at Los Angeles. Patients who met all the inclusion criteria were randomly assigned with the use of a permuted-block design and a 1:1 allocation (in blocks of four to six patients per center) to receive either daily oral cyclophosphamide or matching placebo for 12 months, followed by another year of follow-up without study medication. Treatment of any type was allowed during the second year at the discretion of the primary treating physician.
Baseline Measurements
Baseline measurements, including tests of pulmonary function, scores for skin thickness, measures of the quality of life and functional activity, and indexes of cough and breathlessness, are presented in detail in Supplementary Appendix 3.18-28 High-resolution CT scans were scored for the extent of pure ground-glass opacity, lung fibrosis, honeycombing, and emphysema, as described in Supplementary Appendix 4.
Treatment
Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) and placebo were formulated into matching gelcaps at a dose of 25 mg, and treatment was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram. Assessments to monitor toxic effects included a complete blood count and urinalysis every two to four weeks and a chemistry panel every three months. To preserve blinding of investigators, an independent medication-control officer assessed adverse events and regulated all doses of study medication, in accordance with the study protocol. The study drug was discontinued temporarily or permanently if there was evidence of drug-related toxic effects. Reasons for withholding or changing the dose of the study drug and predefined rules for the reintroduction of the drug or adjustment of the dose are given in Supplementary Appendix 5. A data safety and monitoring board provided oversight of the study. An independent morbidity and mortality review committee reviewed all serious adverse events and rendered opinions regarding their relation to the study.
Serial Monitoring and Outcome Measures
Measurements were made at baseline and at three-month intervals throughout the study, except those made with the baseline instrument of the Mahler Dyspnea Index, which was replaced by the Mahler transitional dyspnea index (with a scale from −9 to +9, with the plus sign indicating improvement and the minus sign indicating worsening) at subsequent visits.16 Lung-volume measurements were repeated at six-month intervals.
Treatment Failure
Treatment failure was defined as an absolute decrease from baseline in the FVC of at least 15 percent of the predicted value occurring at least three months after treatment was initiated and lasting for at least one month. Patients whose response met this definition were withdrawn from the double-blind phase of the study but were encouraged to continue scheduled visits that included spirometry, the administration of questionnaires, and other study procedures. These patients were informed of their treatment assignment and offered open-label therapy with cyclophosphamide.
Statistical Analysis
We estimated that we would need to enroll 163 patients, given an expected mean (±SD) annual decline in the FVC of 9±16 percent of the predicted value2,4-6 and a dropout rate of 15 percent, to achieve a two-sided alpha level of 0.05 and a statistical power of 90 percent. A prespecified analysis of covariance was used to assess treatment effects, adjusted for baseline values and treatment group, with the FVC (expressed as a percentage of the predicted value) at 12 months identified as the primary outcome. A Huber covariance estimation and testing procedure was used, because the data were not normally distributed and included influential extreme values.29 Patients for whom outcome measures at six months or more were not available or whose primary outcome data were technically not interpretable were excluded from analysis. For all remaining patients who withdrew prematurely, a generalized-estimating-equation regression model was fitted, and data missing at 12 months were imputed. At 24 months after randomization, the FVC was the prespecified primary end point; the analysis was based on a longitudinal model that included terms for treatment and time and an interaction between treatment and time with the baseline FVC included in the model.
Other planned analyses of the primary outcome included a nonparametric analysis with a modified Wilcoxon score test,30 in which the FVC at 12 months and the time to death were considered a combined end point, and an extension of the covariance analysis in which the baseline score for fibrosis (the mean reading by two independent radiologists of the worst degree of fibrosis in any region of the baseline high-resolution CT, as described in Supplementary Appendix 4) was used as an additional covariate.
Prespecified secondary outcomes included values at month 12, adjusted for baseline values, for total lung capacity (expressed as a percentage of the predicted value), DlCO, the diffusing capacity adjusted for alveolar volume (Dl:Va), the disability index of the Health Assessment Questionnaire (HAQ), and the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36). No adjustment was made to the P values for these multiple variables. A post hoc analysis of scores for skin thickness was performed in a similar fashion. The three subscales and the summed focal score for the transitional dyspnea index (a secondary outcome) were analyzed with the use of a mixed-model method.16
The data were collected, held, and analyzed in a secure manner at the data coordinating center, with frequent review by the data and safety monitoring board. The statistical analyses were performed with SAS software (version 9.1, SAS), where appropriate. Bristol-Myers Squibb, the manufacturer of the oral cyclophosphamide used in the study, donated the drug but had no role in the design or conduct of the study or the analysis of the data.
Results
Enrollment and Baseline Characteristics
The disposition of the 267 patients who underwent screening and of the 158 eligible patients who underwent randomization is shown in Figure 1Figure 1
Screening, Enrollment, and Outcomes.. Baseline characteristics of those who underwent randomization are listed in Table 1Table 1
Baseline Characteristics of 158 Patients. and summarized in Supplementary Appendix 6. There were no significant differences between the two groups except that the scores for the HAQ disability index were significantly lower (indicating greater health) in the placebo group than in the cyclophosphamide group.The frequency, type, and severity of baseline findings on high-resolution CT are described in detail in Supplementary Appendix 7. Ground-glass opacity, a criterion for entry into the study, was present in 90.1 percent of the patients. Fibrosis was the most common finding on high-resolution CT (89.5 percent of the patients), with 35.8 percent of the patients having evidence of honeycombing. Pulmonary-artery enlargement was rare (1.9 percent of the patients). All abnormalities were most commonly found in the lower lung zones. There were no significant differences between the two groups in the extent of parenchymal abnormalities.
The frequency of positive findings on baseline examination of BAL fluid and the mean percentages of neutrophils and eosinophils are shown in Supplementary Appendix 7. Of 144 patients whose BAL-fluid results could be evaluated cytologically, 70.8 percent had evidence of alveolitis according to the study criteria. The frequency and severity of findings on examination of BAL fluid were similar in the two groups. The proportions of eligible patients whose condition fulfilled the criteria for evidence of alveolitis on high-resolution CT, examination of BAL fluid, or both are given in Supplementary Appendix 8.
Responses to Treatment
Of a total of 158 patients, 3 assigned to placebo and 1 assigned to cyclophosphamide withdrew before starting the study treatment and were not included in the analysis. A number of patients who received at least one dose of study medication withdrew from the study, had conditions that met the protocol definition of treatment failure, or died (Figure 1). A total of 20 patients in the cyclophosphamide group and 13 in the placebo group withdrew within 12 months after randomization, most of them because of adverse events or serious adverse events. Three patients in the cyclophosphamide group had treatment failure, as compared with five in the placebo group. Five patients died during the first 12 months, two in the cyclophosphamide group and three in the placebo group. A total of 54 patients (68.4 percent) in the cyclophosphamide group and 55 (69.6 percent) in the placebo group completed all 12 months of treatment. However, a number of those who withdrew, had treatment failure, or died had completed at least the six-month visit, allowing their end-point results to be imputed and included in the analysis. One patient in the placebo group was not included because the results of spirometry were technically unsatisfactory. Thus, data on 145 patients (91.8 percent), including 73 in the cyclophosphamide group and 72 in the placebo group, were evaluated for the primary outcome. Baseline values and outcomes at month 12 for these 145 patients, as well as mean (±SE) changes in these values, adjusted with the use of Huber estimation,29 are shown in Table 2Table 2
Change in Values from Baseline to Month 12..Prespecified Primary Outcome
When the baseline FVC was used as the only covariate in the Huber model (primary analysis), the adjusted mean absolute difference in FVC at 12 months between the cyclophosphamide group and the placebo group was 2.53 percent (95 percent confidence interval, 0.28 to 4.79 percent), favoring cyclophosphamide (P<0.03). When both the baseline FVC and the worst score for fibrosis at baseline on high-resolution CT were included in the model (in the secondary analysis of the primary outcomes), the adjusted mean absolute difference in the FVC at 12 months between the two groups increased to 2.97 percent (95 percent confidence interval, 0.75 to 5.19 percent), favoring cyclophosphamide (P=0.009). We used regression analysis to evaluate the effect of the baseline score for fibrosis on the FVC at 12 months (Figure 2AFigure 2
The Percentage of Predicted FVC at 12 Months and Changes in the Percentage of Predicted FVC from Baseline to 12 Months.). In the placebo group, the regression slope was significantly negative (−2.01 percent of the predicted FVC per unit score for fibrosis, P=0.006), indicating a greater decline in FVC over time among those who had more severe fibrosis at baseline. By comparison, the difference from 0 in the regression slope in the cyclophosphamide group (0.96 percent of the predicted FVC per unit score for fibrosis) was not significant (P=0.26). The difference between the regression slopes in the two groups was significant (P<0.009), suggesting that cyclophosphamide protected against the decrease in FVC in patients with fibrosis. The combined end point of the time to death plus the FVC at 12 months among the 145 patients evaluated also favored cyclophosphamide (P=0.04 with the use of a modified Wilcoxon procedure).30 Prespecified Secondary Outcomes
A significant difference was also found between the cyclophosphamide group and the placebo group in total lung capacity at 12 months (absolute difference in the percent of the predicted value, 4.09 percent favoring cyclophosphamide; 95 percent confidence interval, 0.49 to 7.65 percent; P=0.026). There were no significant differences between the two groups in either the DlCO (absolute difference in the percent of the predicted value, −1.04; P=0.43) at 12 months or in the Dl:Va at 12 months (absolute difference in the percent of the predicted value, 0.0002 percent; P=0.92). Breathlessness is the chief symptom related to scleroderma-related interstitial lung disease. The mean focal score according to the transitional dyspnea index showed a clinically meaningful improvement in dyspnea (by >1 unit) in the cyclophosphamide group (+1.4±0.23), in contrast to a clinically meaningful worsening (by >1 unit) in the placebo group (−1.5±0.43) (Table 2). There were significant differences between the two groups in the focal score (P<0.001) and in the scores for the three-component transitional dyspnea index, which were incorporated into a mixed model (P<0.001) (available in Supplementary Appendix 9). After adjustment for baseline HAQ scores, the adjusted mean HAQ disability scores at 12 months were significantly lower (indicating less disability) in the cyclophosphamide group than in the placebo group, with the difference between the two groups favoring cyclophosphamide (−0.16; 95 percent confidence interval, −0.28 to –0.04; P=0.009).
Among the scores for all the domains and summary components of the SF-36, only those for the vitality domain (7.99; 95 percent confidence interval, 2.18 to 13.8; P=0.007) and the health-transition domain (–0.66; 95 percent confidence interval, –1.02 to –0.30; P=0.003) showed significant between-group differences, both favoring cyclophosphamide. In none of the domains did the scores show a significant improvement with placebo.
Post Hoc Analyses
When pure ground-glass opacity, the presence or degree of neutrophilia, eosinophilia, or both on examination of BAL fluid, or the degree of honeycombing on the baseline high-resolution CT was added as a covariate to the Huber model, it did not significantly affect the FVC at 12 months. Figure 2B shows the distribution of changes in the FVC (in increments or decrements of 5 percent) in the cyclophosphamide group and the placebo group. A significantly greater percentage of patients in the cyclophosphamide group than in the placebo group had any improvement from baseline values in the FVC (P<0.01 by Fisher's exact test). In 85 patients with diffuse disease, scores for skin thickness showed a significant difference between the two groups favoring cyclophosphamide (−3.06; 95 percent confidence interval, –3.54 to –0.52; P=0.008).
Primary Outcome at 24 Months
Measurements of the FVC were available at 24 months for 113 patients and at 15, 18, and 21 months in an additional 3, 5, and 1 patients, respectively (a total of 122 patients were studied beyond 12 months, 62 in the cyclophosphamide group and 60 in the placebo group). In a longitudinal model made with the use of data collected from months 6 to 24, a significant treatment effect was observed, with a mean absolute difference between the two groups of 1.95 percent in the FVC (95 percent confidence interval, 1.2 to 2.6 percent; P<0.01), favoring cyclophosphamide. No interaction between time and treatment was found.
Adverse Events
Details of adverse events that occurred during the one-year double-blind treatment period (year 1) and the subsequent 12 months of follow-up (year 2) are presented in Table 3Table 3
Adverse Events and Serious Adverse Events.. Hematuria, leukopenia, neutropenia, anemia, and pneumonia were more common among patients in the cyclophosphamide group than among those in the placebo group during year 1; the difference between the two groups was significant for leukopenia and neutropenia (P<0.05 by Fisher's exact test). Few adverse events were recorded during year 2. The number of patients with serious adverse events and the total number of these events during year 1 were slightly, but not significantly, higher in the cyclophosphamide group than in the placebo group (17 vs. 11 patients had adverse events; 20 vs. 16 had serious adverse events). A similar trend was observed in year 2. During months 13 to 24 after randomization, four patients in the cyclophosphamide group and three in the placebo group died. In total, 12 patients died during the two years of the study, but none of the deaths were considered to be related to the study treatment.Discussion
This double-blind, randomized, placebo-controlled clinical trial examined the efficacy of oral cyclophosphamide for the treatment of scleroderma-related interstitial lung disease. Our findings indicate a significant, albeit quite modest, treatment effect of cyclophosphamide on changes in the FVC and total lung capacity over a period of one year but no significant effect on measures of gas transfer (DlCO or DlCO:Va). The clinical importance of this small treatment effect on lung physiology is supported by the additional findings that cyclophosphamide improved dyspnea (according to scores for the transitional dyspnea index), skin thickening, and other outcomes, including functional ability (according to the scores for the HAQ disability index) and some health-related measures of the quality of life (vitality and health transition). For example, the transitional dyspnea index focal score improved by 1.4±0.23 in the cyclophosphamide group and worsened by 1.5±0.43 in the placebo group, a difference that is both statistically significant (P<0.001 with the use of a covariance model) and more than twice the minimal clinically significant level of 1.0.31 Analysis of the primary end point at 24 months showed that the treatment effect on the FVC persisted. Although the limitations of this study included a high dropout rate and the potential for inadvertent unblinding, precautions were taken to minimize the effect of these limitations on the outcome of the trial (Supplementary Appendix 10).
An interesting finding was the relationship between fibrosis and the response to cyclophosphamide. Patients in the placebo group who had evidence of more severe fibrosis on baseline high-resolution CT had the greatest declines in FVC during the one-year treatment period; however, the baseline degree of fibrosis had no significant influence on the change in FVC in cyclophosphamide-treated patients in the same period. A significant interaction between fibrosis and treatment was found (P=0.009) (Figure 2A). A possible conclusion from this result is that preexisting fibrosis in our cohort identifies a subgroup of patients with relatively early active systemic sclerosis alveolitis who were at greatest risk for progressive interstitial lung disease unless treated. The potential benefits of treatment with cyclophosphamide need to be weighed against its adverse effects. Although the average number of adverse events per patient during the one-year treatment period was only slightly higher in the cyclophosphamide group (4.0±0.49) than in the placebo group (3.0±0.41), this difference was significant on Poisson analysis (P=0.01). The only adverse events that occurred significantly more often among patients treated with cyclophosphamide were those known to be associated with this drug — namely, leukopenia and neutropenia — which often responded to appropriate dose adjustment. Although five serious adverse events that occurred in the cyclophosphamide group and one that occurred in the placebo group during the one-year treatment period were judged to be treatment-related, the overall number of serious adverse events and deaths was not significantly different between groups during the full two-year study period. Two days after the completion of the 12-month treatment period, however, severe hemorrhagic cystitis developed in one patient in the cyclophosphamide group and has required multiple hospitalizations and a urinary diversion procedure, underscoring the potential for cyclophosphamide to cause serious toxic effects. The potential long-term effects of cyclophosphamide, including its association with bladder cancer32 and other malignant diseases,33,34 were not evaluated in this study.
In summary, we found that one year of treatment with oral cyclophosphamide resulted in a small but significant improvement in the FVC and total lung capacity at 12 months but not in measures of gas transfer. The extent of fibrosis on baseline high-resolution CT, but not other high-resolution CT findings or cellularity on examination of BAL fluid, significantly influenced the primary treatment effect. The beneficial effect of cyclophosphamide on pulmonary function was paralleled by a significant improvement in dyspnea, functional ability, the health-related quality of life, and skin thickness. The favorable effect of cyclophosphamide on FVC was sustained for the two years of the study. Although treatment with cyclophosphamide resulted in a greater number of adverse events than did placebo, the risk–benefit ratio appears to be favorable. Caution regarding the use of cyclophosphamide is still warranted, since potential long-term consequences were not evaluated.
Supported by a grant from the Public Health Service (UO1 HL 60587, to the University of California at Los Angeles Clinical Center) and by grants from the National Heart, Lung, and Blood Institute (UO1 HL 60587 and UO1 HL 60606, to the data coordinating center at the University of California at Los Angeles; UO1 HL 50550, to the University of Medicine and Dentistry of New Jersey; UO1 HL 60895, to the University of Illinois; UO1 HL 60682, to Boston University; UO1 HL 60750, to the Medical University of South Carolina; UO1 HL 60597, to Johns Hopkins School of Medicine; UO1 HL 60794, to Georgetown University; UO1 HL 60839, to the University of Texas at Houston; UO1 HL 60587, to the University of California at San Francisco; UO1 HL 60748, to the University of Alabama at Birmingham; UO1 HL 60587, to the University of Connecticut Health Center, Farmington; UO1 HL 60838, to Wayne State University; and UO1 HL 60823, to the Virginia Mason Research Center); by the National Institute of Arthritis and Musculoskeletal and Skin Diseases; and by a grant from the National Center for Research Resources, National Institutes of Health (5MO1 RR 00865, for the analysis of study data).
No potential conflict of interest relevant to this article was reported.
We are indebted to Bristol-Myers Squibb for supplying cyclophosphamide.
Source Information
From the University of California at Los Angeles, Los Angeles (D.P.T., R.E., P.J.C., J.G., M.D.R., D.E.F., E.A.); Medical University of South Carolina, Charleston (R.S., C.S., M.B.); University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick (J.R.S., D.J.R., V.M.H.); University of Illinois, Chicago (J.V., D.E.S.); Boston University, Boston (A.T., R.S.); Johns Hopkins School of Medicine, Baltimore (R.W., F.W., B.W.); Georgetown University, Washington, D.C. (V.S., C.R.); University of Texas at Houston Medical School, Houston (M. Mayes, E.P.); Wayne State University, Detroit (K.M.); University of California San Francisco, San Francisco (M.K.C., J.G.); University of Alabama, Birmingham (M.O., B.F.); and University of Connecticut Health Center, Farmington (N.R., M. Metersky).
Address reprint requests to Dr. Tashkin at the Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, 10833 Le Conte Ave., Los Angeles, CA 90095-1690, or at dtashkin@mednet.ucla.edu.
Members of the Scleroderma Lung Study Research Group are listed in the Appendix.
Appendix
The following persons and institutions participated in the Scleroderma Lung Study: University of California at Los Angeles (UCLA), Los Angeles: P.J. Clements, D.P. Tashkin, R. Elashoff, J. Goldin, M. Roth, D. Furst, K. Bulpitt, D. Khanna, W.-L.J. Chung, S. Viasco, M. Sterz, L. Woolcock, X. Yan, J. Ho, S. Vasunilashorn, I. da Costa; University of Medicine and Dentistry of New Jersey, New Brunswick: J.R. Seibold, D.J. Riley, J.K. Amorosa, V.M. Hsu, D.A. McCloskey, J.E. Wilson; University of Illinois Chicago, Chicago: J. Varga, D. Schraufnagel, A. Wilbur, D. Lapota, S. Arami, P. Cole-Saffold; Boston University, Boston: R. Simms, A. Theodore, P. Clarke, J. Korn, K. Tobin, M. Nuite; Medical University of South Carolina, Charleston: R. Silver, M. Bolster, C. Strange, S. Schabel, E. Smith, J. Arnold, K. Caldwell, M. Bonner; Johns Hopkins School of Medicine, Baltimore: R. Wise, F. Wigley, B. White, L. Hummers, M. Bohlman, A. Polito, G. Leatherman, E. Forbes, M. Daniel; Georgetown University, Washington, D.C.: V. Steen, C. Read, C. Cooper, S. Wheaton, A. Carey, A. Ortiz; University of Texas at Houston, Houston: M. Mayes, E. Parsley, S. Oldham, T. Filemon, S. Jordan, M. Perry; University of California at San Francisco, San Francisco: K. Connolly, J. Golden, P. Wolters, R. Webb, J. Davis, C. Antolos, C. Maynetto; University of Alabama at Birmingham, Birmingham: B. Fessler, M. Olman, C. Sanders, L. Heck, T. Parkhill; University of Connecticut Health Center, Farmington: N. Rothfield, M. Metersky, R. Cobb, M. Aberles, F. Ingenito, E. Breen; Wayne State University, Detroit: M. Mayes, K. Mubarak, J.L. Granda, J. Silva, Z. Injic, R. Alexander; Virginia Mason Research Center, Seattle: D. Furst, S. Springmeyer, S. Kirkland, J. Molitor, R. Hinke, A. Mondt; Data Safety and Monitoring Board: Harvard Medical School, Boston — T. Thompson; Veterans Affairs Medical Center, Brown University, Providence, R.I. — S. Rounds; Cedars Sinai–UCLA, Los Angeles — M. Weinstein; Clinical Trials Surveys, Baltimore — B. Thompson; Mortality and Morbidity Review Committee: UCLA, Los Angeles — H. Paulus, S. Levy; Johns Hopkins University, Baltimore — D. Martin.
- References
References
1
Steen VD ,Conte C ,Owens GR ,Medsger TA Jr . Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-1289
CrossRef | Web of Science | Medline2
White B ,Moore WC ,Wigley FM ,Xiao HQ ,Wise RA . Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-954
Web of Science | Medline3
Latsi PI ,Wells AU . Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003;15:748-755
CrossRef | Web of Science | Medline4
Silver RM ,Warrick JH ,Kinsella MB ,Staudt LS ,Baumann MH ,Strange C . Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:834-8445
Akesson A ,Scheja A ,Lundin A ,Wollheim F . Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994;37:729-735
CrossRef | Web of Science | Medline6
Steen VD ,Lanz JK Jr ,Conte C ,Owens GR ,Medsger TA Jr . Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 1994;37:1290-1296
CrossRef | Web of Science | Medline7
Davas EM ,Peppas C ,Maragou M ,Alvanou E ,Hondros D ,Dantis PC . Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999;18:455-461
CrossRef | Web of Science | Medline8
Behr J ,Vogelmeier C ,Beinert T , et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996;154:400-406
Web of Science | Medline9
Varai G ,Earle L ,Jimenez SA ,Steinert RM ,Varga J . A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic associated lung disease. J Rheumatol 1998;25:1325-1329
Web of Science | Medline10
Pakas I ,Ioannidis JP ,Malagari K ,Skopouli FN ,Moutsopoulos HM ,Vlachoyiannopoulos PG . Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002;29:298-304
Web of Science | Medline11
Giacomelli R ,Valentin G ,Slasano F , et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731-736
Web of Science | Medline12
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590
CrossRef | Web of Science | Medline13
Medsger TA Jr. Classification, prognosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2004:17-28.
14
BAL Cooperative Group Steering Committee
Web of Science | Medline15
Crapo RO ,Morris AH ,Gardner RM . Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-664
Web of Science | Medline16
Mahler DA ,Weinberg DH ,Wells CK ,Feinstein AR . The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-758
CrossRef | Web of Science | Medline17
Crapo RO ,Morris AH . Standardized single breath normal values of carbon monoxide diffusing capacity. Am Rev Respir Dis 1981;123:185-189
Web of Science | Medline18
American Thoracic Society
Web of Science | Medline19
American Association for Respiratory Care
Medline20
Guidelines for the measurement of respiratory function: recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994;88:165-194
CrossRef | Web of Science | Medline21
American Thoracic Society
Web of Science | Medline22
Black LF ,Hyatt RE . Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969;99:696-702
Web of Science | Medline23
Clements PJ ,Lachenbruch PA ,Seibold JR , et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-1285
Web of Science | Medline24
Petty TL . The National Mucolytic Study: results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990;98:75-83
CrossRef | Web of Science25
Ware JE Jr ,Sherbourne CD . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
CrossRef | Web of Science | Medline26
Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
27
Clements PJ ,Wong WK ,Hurwitz EL , et al. The disability index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001;44:653-661
CrossRef | Web of Science | Medline28
Ferris BG . Epidemiology Standardization Project (American Thoracis Society). Am Rev Respir Dis 1978;118:1-120
Web of Science | Medline29
Huber PJ . Robust regression: asymptotics, conjectures, and Monte Carlo. Ann Statist 1973;1:799-821
CrossRef | Web of Science30
Finkelstein DM ,Schoenfeld DA . Combining mortality and longitudinal measures in clinical trials. Stat Med 1999;18:1341-1354
CrossRef | Web of Science | Medline31
Witek TJ Jr ,Mahler DA . Minimal important difference of the transition dyspnoea index in multinational clinical trial. Eur Respir J 2003;21:267-272
CrossRef | Web of Science | Medline32
Talar-Williams C ,Hijazi YM ,Walther MM , et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-484
Web of Science | Medline33
Baltus JA ,Boersma JW ,Hartman AP ,Vandenbroucke JP . The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983;42:368-373
CrossRef | Web of Science | Medline34
Radis CD ,Kahl LE ,Baker GL , et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year followup study. Arthritis Rheum 1995;38:1120-1127
CrossRef | Web of Science | Medline
- Citing Articles (210)
Citing Articles
1
Dionisio Pérez Campos, Miguel Estévez Del Toro, Aisa Peña Casanovas, Pedro Pablo González Rojas, Lisvenia Morales Sánchez, Ángela Rosa Gutiérrez Rojas. (2012) ¿Son necesarias las dosis elevadas de prednisona para el tratamiento de la neumopatía intersticial en la esclerosis sistémica?. Reumatología Clínica
CrossRef2
R. Hesselstrand, K. Andreasson, D. M. Wuttge, G. Bozovic, A. Scheja, T. Saxne. (2012) Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease. Rheumatology
CrossRef3
Richard K Burt, Mahai Gheorghiade, Sanjiv Shah, Eric Ruderman, James Schroeder. (2012) Haemopoietic stem-cell transplantation for systemic sclerosis – Authors' reply. The Lancet 379:9812, 219-220
CrossRef4
Timothy J. Vece, Leland L. Fan. (2011) Diagnosis and Management of Diffuse Lung Disease in Children. Paediatric Respiratory Reviews 12:4, 238-242
CrossRef5
V. Navaratnam, N. Ali, C.J.P. Smith, T. McKeever, A. Fogarty, R.B. Hubbard. (2011) Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis?. Respiratory Medicine 105:12, 1925-1930
CrossRef6
Philip J. Clements, Yannick Allanore, Dinesh Khanna, Minjit Singh, Daniel E. Furst. (2011) Arthritis in Systemic Sclerosis: Systematic Review of the Literature and Suggestions for the Performance of Future Clinical Trials in Systemic Sclerosis Arthritis. Seminars in Arthritis and Rheumatism
CrossRef7
Dinesh Khanna, Rajeev Saggar, Maureen D. Mayes, Fereidoun Abtin, Philip J. Clements, Paul Maranian, Shervin Assassi, Rajan Saggar, Ram R. Singh, Daniel E. Furst. (2011) A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis & Rheumatism 63:11, 3540-3546
CrossRef8
Nancy J. Olsen. (2011) Scleroderma: The Need for Extreme Remedies. The American Journal of the Medical Sciences 342:5, 416-421
CrossRef9
Richard K. Burt, Francesca Milanetti. (2011) Hematopoietic stem cell transplantation for systemic sclerosis. Current Opinion in Rheumatology 23:6, 519-529
CrossRef10
Ayumi Yoshizaki, Koichi Yanaba, Asako Ogawa, Yoshihide Asano, Takafumi Kadono, Shinichi Sato. (2011) Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis & Rheumatism 63:11, 3575-3585
CrossRef11
Janet Pope. (2011) Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), Physician- and Patient-Rated Global Assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials. Arthritis Care & Research 63:S11, S98-S111
CrossRef12
Carmen Pilar Simeón-Aznar, Vicent Fonollosa-Plá, Carles Tolosa-Vilella, Albert Selva-O’Callaghan, Roser Solans-Laqué, Miquel Vilardell-Tarrés. (2011) Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clinical Rheumatology 30:11, 1393-1398
CrossRef13
Takehiro Takahashi, Yoshihide Asano, Eisuke Amiya, Masaru Hatano, Zenshiro Tamaki, Atsuko Ozeki, Aya Watanabe, Shuichi Kawarasaki, Tomoko Nakao, Takashi Taniguchi, Yohei Ichimura, Tetsuo Toyama, Masafumi Watanabe, Yasunobu Hirata, Ryozo Nagai, Shinichi Sato. (2011) Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases. Modern Rheumatology
CrossRef14
J A Snowden, R Saccardi, M Allez, S Ardizzone, R Arnold, R Cervera, C Denton, C Hawkey, M Labopin, G Mancardi, R Martin, J J Moore, J Passweg, C Peters, M Rabusin, M Rovira, J M van Laar, D Farge. (2011) Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation
CrossRef15
C. Egla Rabinovich. (2011) Challenges in the diagnosis and treatment of juvenile systemic sclerosis. Nature Reviews Rheumatology 7:11, 676-680
CrossRef16
Joshua J Solomon, Kevin K Brown. (2011) Management of interstitial lung disease in systemic sclerosis. International Journal of Clinical Rheumatology 6:5, 503-515
CrossRef17
Dinesh Khanna, Chi-Hong Tseng, Niloofar Farmani, Virginia Steen, Daniel E. Furst, Philip J. Clements, Michael D. Roth, Jonathan Goldin, Robert Elashoff, James R. Seibold, Rajeev Saggar, Donald P. Tashkin. (2011) Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group. Arthritis & Rheumatism 63:10, 3078-3085
CrossRef18
Ayumi Yoshizaki, Koichi Yanaba, Asako Ogawa, Yohei Iwata, Fumihide Ogawa, Motoi Takenaka, Kazuhiro Shimizu, Yoshihide Asano, Takafumi Kadono, Shinichi Sato. (2011) The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis & Rheumatism 63:10, 3086-3097
CrossRef19
Hyun J. Kim, Matthew S. Brown, Robert Elashoff, Gang Li, David W. Gjertson, David A. Lynch, Diane C. Strollo, Eric Kleerup, Daniel Chong, Sumit K. Shah, Shama Ahmad, Fereidoun Abtin, Donald P. Tashkin, Jonathan G. Goldin. (2011) Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. European Radiology
CrossRef20
Isabel Almeida, Raquel Faria, Pedro Vita, Carlos Vasconcelos. (2011) Systemic sclerosis refractory disease: From the skin to the heart. Autoimmunity Reviews 10:11, 693-701
CrossRef21
Michael D. Roth, Chi-Hong Tseng, Philip J. Clements, Daniel E. Furst, Donald P. Tashkin, Jonathan G. Goldin, Dinesh Khanna, Eric C. Kleerup, Ning Li, David Elashoff, Robert M. Elashoff, . (2011) Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis & Rheumatism 63:9, 2797-2808
CrossRef22
Anagha A. Divekar, Dinesh Khanna, Fereidoun Abtin, Paul Maranian, Rajeev Saggar, Rajan Saggar, Daniel E. Furst, Ram Raj Singh. (2011) Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4+ T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clinical Immunology
CrossRef23
Jérôme Le Pavec, Reda E. Girgis, Noah Lechtzin, Stephen C. Mathai, David Launay, Laura K. Hummers, Ari Zaiman, Olivier Sitbon, Gérald Simonneau, Marc Humbert, Paul M. Hassoun. (2011) Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis & Rheumatism 63:8, 2456-2464
CrossRef24
Abhishek Abhishek, Ramin Yazdani, Fiona Pearce, Marian Regan, Ken Lim, Richard Hubbard, Peter Lanyon. (2011) Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide. Clinical Rheumatology 30:8, 1099-1104
CrossRef25
P. Moinzadeh, C.P. Denton, D. Abraham, V. Ong, N. Hunzelmann, B. Eckes, T. Krieg. (2011) Biomarkers for skin involvement and fibrotic activity in scleroderma. Journal of the European Academy of Dermatology and Venereologyno-no
CrossRef26
Ye Gan, Ronald Reilkoff, Xueyan Peng, Thomas Russell, Qingsheng Chen, Susan K. Mathai, Robert Homer, Mridu Gulati, Jonathan Siner, Jack Elias, Richard Bucala, Erica Herzog. (2011) Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis & Rheumatism 63:8, 2484-2494
CrossRef27
Roozbeh Sharif, Maureen D. Mayes, Perry M. Nicassio, Emilio B. Gonzalez, Hilda Draeger, Terry A. McNearney, Rosa M. Estrada-Y-Martin, Deepthi K. Nair, John D. Reveille, Frank C. Arnett, Shervin Assassi. (2011) Determinants of Work Disability in Patients with Systemic Sclerosis: A Longitudinal Study of the GENISOS Cohort. Seminars in Arthritis and Rheumatism 41:1, 38-47
CrossRef28
Richard K Burt, Sanjiv J Shah, Karin Dill, Thomas Grant, Mihai Gheorghiade, James Schroeder, Robert Craig, Ikuo Hirano, Karin Marshall, Eric Ruderman, Borko Jovanovic, Francesca Milanetti, Sandeep Jain, Kristin Boyce, Amy Morgan, James Carr, Walter Barr. (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. The Lancet 378:9790, 498-506
CrossRef29
Chris T Derk. (2011) Disease-modifying drugs for systemic sclerosis: why have we not found them yet?. Expert Review of Clinical Immunology 7:4, 399-401
CrossRef30
Hadi Poormoghim, Maziar Moradi Lakeh, Mastoureh Mohammadipour, Faezeh Sodagari, Neda Toofaninjed. (2011) Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatology International
CrossRef31
Akiko Tochimoto, Yasushi Kawaguchi, Masako Hara, Mutsuto Tateishi, Chikako Fukasawa, Kae Takagi, Emi Nishimagi, Yuko Ota, Yasuhiro Katsumata, Takahisa Gono, Eiichi Tanaka, Hisashi Yamanaka. (2011) Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Modern Rheumatology 21:3, 296-301
CrossRef32
Dhanita Khanna. (2011) Diagnosis and treatment of systemic and localized scleroderma. Expert Review of Dermatology 6:3, 287-302
CrossRef33
C. Egla Rabinovich. (2011) Pulmonary Complications of Childhood Rheumatic Disease. Paediatric Respiratory Reviews
CrossRef34
Daniel E. Furst, Chi-Hong Tseng, Philip J. Clements, Charlie Strange, Donald P. Tashkin, Michael D. Roth, Dinesh Khanna, Ning Li, Robert Elashoff, Dean E. Schraufnagel. (2011) Adverse Events during the Scleroderma Lung Study. The American Journal of Medicine 124:5, 459-467
CrossRef35
Gerard Espinosa, Carmen Pilar Simeón, Miguel Ángel Plasín, Antoni Xaubet, Xavier Muñoz, Vicent Fonollosa, Ricard Cervera, Miquel Vilardell. (2011) Eficacia de la ciclofosfamida endovenosa en el tratamiento de la enfermedad pulmonar intersticial asociada a la esclerosis sistémica. Archivos de Bronconeumología 47:5, 239-245
CrossRef36
Cecilia Chighizola, Voon H Ong, Christopher P Denton. (2011) Cyclophosphamide as disease-modifying therapy for scleroderma: pros and cons. International Journal of Clinical Rheumatology 6:2, 219-230
CrossRef37
Herbert Y. Reynolds. (2011) Bronchoalveolar Lavage and Other Methods to Define the Human Respiratory Tract Milieu in Health and Disease. Lung 189:2, 87-99
CrossRef38
Jérôme Pavec, David Launay, Stephen C. Mathai, Paul M. Hassoun, Marc Humbert. (2011) Scleroderma Lung Disease. Clinical Reviews in Allergy & Immunology 40:2, 104-116
CrossRef39
Rebecca L Manno, Laura K Hummers. (2011) Aging and scleroderma. Aging Health 7:2, 231-242
CrossRef40
Ferit zuhur, Sayid Shafi Zuhur, Cigdem Zuhur, Benan Musellim, Gul Ongen. (2011) Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey. Rheumatology International
CrossRef41
Guillaume Bussone, Luc Mouthon. (2011) Interstitial lung disease in systemic sclerosis. Autoimmunity Reviews 10:5, 248-255
CrossRef42
Wong-Shian Huang, Jen-pei Liu, Chin-Fu Hsiao. (2011) An alternative phase II/III design for continuous endpoints. Pharmaceutical Statistics 10:2, 105-114
CrossRef43
Diogo S. Domiciano, Eloisa Bonfá, Claudia T. L. Borges, Ronaldo A. Kairalla, Vera L. Capelozzi, Edwin Parra, Romy Beatriz Christmann. (2011) A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clinical Rheumatology 30:2, 223-229
CrossRef44
Faye N. Hant, Richard M. Silver. (2011) Biomarkers of Scleroderma Lung Disease: Recent Progress. Current Rheumatology Reports 13:1, 44-50
CrossRef45
Elizabeth Schulman, Kun Chen, Gregory Saboeiro, Abraham Sanders, Kyriakos Kirou, Robert F. Spiera, Anne R. Bass, Doruk Erkan. (2011) Cyclophosphamide Responsive Interstitial Lung Disease in “Overlap Syndrome”. HSS Journal 7:1, 99-105
CrossRef46
Jessica Gordon, Robert Spiera. (2011) Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies. International Journal of Rheumatology 2011, 1-8
CrossRef47
Myung-Eun Song, Jisoo Lee, Sun-Hee Roh. (2011) Impact of Rheumatologic Consultations on Detecting Interstitial Lung Disease Associated with Connective Tissue Disease. Journal of Rheumatic Diseases 18:3, 168
CrossRef48
Francesco Zulian, James T. Cassidy. 2011. THE SYSTEMIC SCLERODERMAS AND RELATED DISORDERS. , 414-437.
CrossRef49
Gerard Espinosa, Carmen Pilar Simeon, Miguel Angel Plasin, Antoni Xaubet, Xavier Muñoz, Vicent Fonollosa, Ricard Cervera, Miquel Vilardell. (2011) Efficacy of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis. Archivos de Bronconeumología (English Edition) 47:5, 239-245
CrossRef50
Dimitrios Daoussis, Stamatis-Nick C. Liossis, Georgios Yiannopoulos, Andrew P. Andonopoulos. (2011) B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence. International Journal of Rheumatology 2011, 1-7
CrossRef51
Xin Huang, Gang Li, Robert M. Elashoff, Jianxin Pan. (2011) A general joint model for longitudinal measurements and competing risks survival data with heterogeneous random effects. Lifetime Data Analysis 17:1, 80-100
CrossRef52
Aryeh Fischer, Roland M. du Bois. 2011. Lung. , 847-864.
CrossRef53
Y. Furuya, Y. Okazaki, K. Kaji, S. Sato, K. Takehara, M. Kuwana. (2010) Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. Rheumatology 49:12, 2375-2380
CrossRef54
Julie Baraut, Laurence Michel, Franck Verrecchia, Dominique Farge. (2010) Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmunity Reviews 10:2, 65-73
CrossRef55
Karen Au, Maureen D. Mayes, Paul Maranian, Philip J. Clements, Dinesh Khanna, Virginia D. Steen, Donald Tashkin, Michael D. Roth, Robert Elashoff, Daniel E. Furst. (2010) Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care & Research 62:12, 1772-1778
CrossRef56
Maria De Santis, Silvia Laura Bosello, Giusy Peluso, Michela Pinnelli, Stefano Alivernini, Gaetano Zizzo, Mario Bocci, Annunziata Capacci, Giuseppe La Torre, Alice Mannocci, Gabriella Pagliari, Francesco Varone, Roberto Pistelli, Francesco Maria Danza, Gianfranco Ferraccioli. (2010) Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. The Clinical Respiratory Journalno-no
CrossRef57
Rebecca Manno, Francesco Boin. (2010) Immunotherapy of systemic sclerosis. Immunotherapy 2:6, 863-878
CrossRef58
Athanasios Koutroumpas, Athanasios Ziogas, Ioannis Alexiou, Georgia Barouta, Lazaros I. Sakkas. (2010) Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clinical Rheumatology 29:10, 1167-1168
CrossRef59
Silvia Bellando-Randone, Serena Guiducci, Marco Matucci-Cerinic. (2010) Patient subgroups and potential risk factors in systemic sclerosis: is there a possibility of an early diagnosis?. International Journal of Clinical Rheumatology 5:5, 555-564
CrossRef60
Faye N. Hant, Laura B. Herpel, Richard M. Silver. (2010) Pulmonary Manifestations of Scleroderma and Mixed Connective Tissue Disease. Clinics in Chest Medicine 31:3, 433-449
CrossRef61
Keith C. Meyer, Catherine Decker, Robert Baughman. (2010) Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases. Clinics in Chest Medicine 31:3, 565-588
CrossRef62
N. M. Thoua, C. Bunce, G. Brough, A. Forbes, A. V. Emmanuel, C. P. Denton. (2010) Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology 49:9, 1770-1775
CrossRef63
Otylia Kowal-Bielecka, Krzysztof Kowal, Kristin B. Highland, Richard M. Silver. (2010) Bronchoalveolar Lavage Fluid in Scleroderma Interstitial Lung Disease: Technical Aspects and Clinical Correlations: Review of the Literature. Seminars in Arthritis and Rheumatism 40:1, 73-88
CrossRef64
Ayumi Yoshizaki, Koichi Yanaba, Asako Yoshizaki, Yohei Iwata, Kazuhiro Komura, Fumihide Ogawa, Motoi Takenaka, Kazuhiro Shimizu, Yoshihide Asano, Minoru Hasegawa, Manabu Fujimoto, Shinichi Sato. (2010) Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis & Rheumatism 62:8, 2476-2487
CrossRef65
Marie-Elise Truchetet, Nicolo C Brembilla, Elisa Montanari, Carlo Chizzolini. (2010) T-cell subsets in scleroderma patients. Expert Review of Dermatology 5:4, 403-415
CrossRef66
P. Mangat, M. Conron, E. Gabbay, S. M. Proudman, . (2010) Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians. Internal Medicine Journal 40:7, 494-502
CrossRef67
Luc Mouthon, Alice Bérezné, Loïc Guillevin, Dominique Valeyre. (2010) Therapeutic options for systemic sclerosis related interstitial lung diseases. Respiratory Medicine 104, S59-S69
CrossRef68
Dinesh Khanna, Christopher P. Denton. (2010) Evidence-based management of rapidly progressing systemic sclerosis. Best Practice & Research Clinical Rheumatology 24:3, 387-400
CrossRef69
Susan K Mathai, Mridu Gulati, Xueyan Peng, Thomas R Russell, Albert C Shaw, Ami N Rubinowitz, Lynne A Murray, Jonathan M Siner, Danielle E Antin-Ozerkis, Ruth R Montgomery, Ronald A S Reilkoff, Richard J Bucala, Erica L Herzog. (2010) Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Laboratory Investigation 90:6, 812-823
CrossRef70
Nicolas Hunzelmann, Thomas Krieg. (2010) Scleroderma: from pathophysiology to novel therapeutic approaches. Experimental Dermatology 19:5, 393-400
CrossRef71
Enríquez-Casillas RUBÉN, Vázquez-Rodríguez MANUEL, Ochoa-Ramírez AGUSTÍN, Miguel HUERTA, Fraga-Mouret ANTONIO, Delgado-Enciso IVÁN. (2010) Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma. The Journal of Dermatology 37:4, 323-329
CrossRef72
Brent W. Kinder, Cyrus Shariat, Harold R. Collard, Laura L. Koth, Paul J. Wolters, Jeffrey A. Golden, Ralph J. Panos, Talmadge E. King. (2010) Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function. Lung 188:2, 143-149
CrossRef73
Diane Strollo, Jonathan Goldin. (2010) Imaging Lung Disease in Systemic Sclerosis. Current Rheumatology Reports 12:2, 156-161
CrossRef74
M. J. D. Goodfield, S. K. Jones, D. J. Veale. 2010. The ‘Connective Tissue Diseases’. , 1-138.
CrossRef75
Timothy J. Vece, Leland L. Fan. (2010) Interstitial Lung Disease in Children Older Than 2 Years. Pediatric Allergy, Immunology, and Pulmonology 23:1, 33-41
CrossRef76
Brent Kinder, Francis X. McCormack. (2010) Clinical Trials for Rare Lung Diseases: Lessons from Lymphangioleiomyomatosis. Lymphatic Research and Biology 8:1, 71-79
CrossRef77
L. Mouthon, C. Mestre, A. Berezne, S. Poiraudeau, C. Marchand, P. Guilpain, L. Guillevin, O. Launay. (2010) Low influenza vaccination rate among patients with systemic sclerosis. Rheumatology 49:3, 600-606
CrossRef78
M Colaci, M Sebastiani, D Giuggioli, A Manfredi, P Spagnolo, F Luppi, L Richeldi, C Ferri. (2010) Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. Scandinavian Journal of Rheumatology 39:2, 155-159
CrossRef79
S.I. Nihtyanova, E.C. Tang, J.G. Coghlan, A.U. Wells, C.M. Black, C.P. Denton. (2010) Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 103:2, 109-115
CrossRef80
Alicia Peterson, John Varga. (2010) Cyclophosphamide: A Novel Treatment of Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis?. Current Rheumatology Reports 12:1, 4-7
CrossRef81
K. Yanaba, A. Yoshizaki, E. Muroi, T. Hara, F. Ogawa, K. Shimizu, M. Hasegawa, M. Fujimoto, K. Takehara, S. Sato. (2010) CCL13 is a promising diagnostic marker for systemic sclerosis. British Journal of Dermatology 162:2, 332-336
CrossRef82
R. M. du Bois. (2010) Strategies for treating idiopathic pulmonary fibrosis. Nature Reviews Drug Discovery 9:2, 129-140
CrossRef83
D. Daoussis, S.-N. C. Liossis, A. C. Tsamandas, C. Kalogeropoulou, A. Kazantzi, C. Sirinian, M. Karampetsou, G. Yiannopoulos, A. P. Andonopoulos. (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49:2, 271-280
CrossRef84
T. Schmeiser, U. Müller-Ladner. (2010) EULAR-Empfehlungen zur Behandlung der systemischen Sklerose. Zeitschrift für Rheumatologie 69:1, 87-92
CrossRef85
Wan-Hee Yoo. (2010) Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatology International
CrossRef86
Sonosuke YUKAWA, Kunihiro YAMAOKA, Norifumi SAWAMUKAI, Shohei SHIMAJIRI, Kazuyoshi SAITO, Yoshiya TANAKA. (2010) Involvement of mast cells in systemic sclerosis. Japanese Journal of Clinical Immunology 33:2, 81-86
CrossRef87
Kunio Kawanishi, Minako Koike, Kazuo Kimura, Yuko Sasaki, Masaki Takahashi, Keiko Matsugami, Noriaki Nakagawa, Masayuki Nakano, Takashi Takei, Kousaku Nitta. (2010) An autopsy case of untreated systemic sclerosis with renal crisis and myocarditis. Nihon Toseki Igakkai Zasshi 43:10, 865-871
CrossRef88
Keith M. Sullivan, Paolo Muraro, Alan Tyndall. (2010) Hematopoietic Cell Transplantation for Autoimmune Disease: Updates from Europe and the United States. Biology of Blood and Marrow Transplantation 16:1, S48-S56
CrossRef89
Yoshihide ASANO. (2010) Future treatments in systemic sclerosis. The Journal of Dermatology 37:1, 54-70
CrossRef90
A. Prasse, J.U. Holle, J. Müller-Quernheim. (2010) Lungenfibrose. Der Internist 51:1, 6-13
CrossRef91
Paul A. Monach, Lindsay M. Arnold, Peter A. Merkel. (2010) Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis & Rheumatism 62:1, 9-21
CrossRef92
Peter K. Wung, Fredrick M. Wigley. 2010. Management of Systemic Sclerosis and Raynaud's Phenomenon. , 157-165.
CrossRef93
O. Distler, S. Gay. (2010) Sklerodermie. Der Internist 51:1, 30-38
CrossRef94
D. Khanna, C.-H. Tseng, D. E. Furst, P. J. Clements, R. Elashoff, M. Roth, D. Elashoff, D. P. Tashkin, . (2009) Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. Rheumatology 48:12, 1537-1540
CrossRef95
Niamh P Quillinan, Christopher P Denton. (2009) Disease-modifying treatment in systemic sclerosis: current status. Current Opinion in Rheumatology 21:6, 636-641
CrossRef96
Joao A de Andrade, Victor J Thannickal. (2009) Innovative approaches to the therapy of fibrosis. Current Opinion in Rheumatology 21:6, 649-655
CrossRef97
David A. Lynch. (2009) Lung Disease Related to Collagen Vascular Disease. Journal of Thoracic Imaging 24:4, 299-309
CrossRef98
H.-P. Hauber, D. Kirsten. (2009) Interstitielle Lungenerkrankungen. Zeitschrift für Rheumatologie 68:8, 621-629
CrossRef99
A. Schnabel, M. Reuter. (2009) Interstitielle Lungenkrankheit bei Kollagenosen. Zeitschrift für Rheumatologie 68:8, 650-657
CrossRef100
Romy Beatriz Christmann Souza, André Regis Macedo, Kátia Akemi Kuruma, Patricia Andrade Macedo, Claudia Teresa Lobato Borges. (2009) Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis. Clinical Rheumatology 28:10, 1207-1212
CrossRef101
Herbert Y Reynolds. (2009) Present status of bronchoalveolar lavage in interstitial lung disease. Current Opinion in Pulmonary Medicine 15:5, 479-485
CrossRef102
Odile Launay, Loic Guillevin, Luc Mouthon. (2009) Immunizations in Adult Patients with Systemic Sclerosis. Annals of the New York Academy of Sciences 1173:1, 610-618
CrossRef103
(2009) Lost in translation; from animal models of pulmonary fibrosis to human disease. Respirology 14:7, 915-916
CrossRef104
Ajay WANCHU, Bettadpura Shamanna SURYANARYANA, Shefali SHARMA, Aman SHARMA, Pradeep BAMBERY. (2009) High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. International Journal of Rheumatic Diseases 12:3, 239-242
CrossRef105
Marie Hudson, Brett D. Thombs, Russell Steele, Pantelis Panopalis, Evan Newton, Murray Baron, . (2009) Health-related quality of life in systemic sclerosis: A systematic review. Arthritis & Rheumatism 61:8, 1112-1120
CrossRef106
Emer Kelly, Jonathan D. Dodd, Michael P. Keane. (2009) Mycophenolate in the Treatment of Scleroderma-Associated Interstitial Lung Disease and Other Collagen Vascular Disease-Related Interstitial Lung Disease. Clinical Pulmonary Medicine 16:4, 194-198
CrossRef107
Francesco Boin, Fredrick Wigley. (2009) Connective tissue diseases: Immunosuppressive therapy in SSc: what is the target?. Nature Reviews Rheumatology 5:7, 357-358
CrossRef108
Vasiliki Kalliopi K. Bournia, Panayiotis G. Vlachoyiannopoulos, Carlo Selmi, Haralampos M. Moutsopoulos, M. Eric Gershwin. (2009) Recent Advances in the Treatment of Systemic Sclerosis. Clinical Reviews in Allergy & Immunology 36:2-3, 176-200
CrossRef109
A. U. Wells, V. Steen, G. Valentini. (2009) Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology 48:Supplement 3, iii40-iii44
CrossRef110
A. Tyndall, M. Matucci-Cerinic, U. Muller-Ladner. (2009) Future targets in the management of systemic sclerosis. Rheumatology 48:Supplement 3, iii49-iii53
CrossRef111
Wenhua Hu, Gang Li, Ning Li. (2009) A Bayesian approach to joint analysis of longitudinal measurements and competing risks failure time data. Statistics in Medicine 28:11, 1601-1619
CrossRef112
Lesley Ann Saketkoo, Luis R. Espinoza. (2009) Experience of Mycophenolate Mofetil in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects. The American Journal of the Medical Sciences 337:5, 329-335
CrossRef113
Aurelien Amiot, Francisca Joly, Arnaud Alves, Yves Panis, Yoram Bouhnik, Bernard Messing. (2009) Long-Term Outcome of Chronic Intestinal Pseudo-Obstruction Adult Patients Requiring Home Parenteral Nutrition. The American Journal of Gastroenterology 104:5, 1262-1270
CrossRef114
Kristine Phillips, Cathryn Byrne-Dugan, Eric Batterson, James R. Seibold. (2009) Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis. Nature Reviews Rheumatology 5:4, 225-228
CrossRef115
Karen Au, Dinesh Khanna, Philip J. Clements, Daniel E. Furst, Donald P. Tashkin. (2009) Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. Current Rheumatology Reports 11:2, 111-119
CrossRef116
Aryeh Fischer, Kevin K. Brown, Stephen K. Frankel. (2009) Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease. Clinical Pulmonary Medicine 16:2, 74-80
CrossRef117
Aryeh Fischer. (2009) Interstitial Lung Disease. JCR: Journal of Clinical Rheumatology 15:2, 95-99
CrossRef118
Marie Hudson, Brett Thombs, Murray Baron, . (2009) Time to diagnosis in systemic sclerosis: Is sex a factor?. Arthritis & Rheumatism 61:2, 274-278
CrossRef119
Ning Li, Robert M. Elashoff, Gang Li. (2009) Robust Joint Modeling of Longitudinal Measurements and Competing Risks Failure Time Data. Biometrical Journal 51:1, 19-30
CrossRef120
Robert Lafyatis, Eugene Kissin, Michael York, Giuseppina Farina, Kerry Viger, Marvin J. Fritzler, Peter A. Merkel, Robert W. Simms. (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis & Rheumatism 60:2, 578-583
CrossRef121
B. Maurer, M. Walder, R.E. Gay, S. Gay, O. Distler. (2009) Systemische Sklerose. Zeitschrift für Rheumatologie 68:1, 37-43
CrossRef122
Max Shenin, Manisha Naik, Chris T Derk. (2009) Advances in disease-specific treatment of systemic sclerosis. International Journal of Clinical Rheumatology 4:1, 67-73
CrossRef123
Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, Reda E. Girgis. (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis & Rheumatism 60:2, 569-577
CrossRef124
Tamera J Corte, Athol U Wells. (2009) Treatment of idiopathic interstitial pneumonias. Expert Review of Respiratory Medicine 3:1, 81-91
CrossRef125
Adam S. Morgenthau, Maria L. Padilla. (2009) Spectrum of Fibrosing Diffuse Parenchymal Lung Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:1, 2-23
CrossRef126
K. Marten, V. Dicken, C. Kneitz, M. Höhmann, W. Kenn, D. Hahn, C. Engelke. (2009) Interstitial lung disease associated with collagen vascular disorders: disease quantification using a computer-aided diagnosis tool. European Radiology 19:2, 324-332
CrossRef127
Hironobu IHN. (2009) Nishi Nihon Hifuka 71:4, 428-433
CrossRef128
C. Egla Rabinovich, Edward Fels, Joseph Shanahan, J. Marc Majure, Thomas M. Murphy. 2009. Pulmonary Manifestations of Rheumatoid Diseases. , 201-240.
CrossRef129
Toshihiko Yagyu. (2009) A Case of Systemic Sclerosis Accompanied with Ulcerative Colitis. Nippon Daicho Komonbyo Gakkai Zasshi 62:7, 471-474
CrossRef130
Franck Verrecchia, Ying Wang, Lavinia Vija, Dominique Farge. (2009) Evidence of an antifibrotic effect of immunosuppressive drugs: applications in the treatment of systemic sclerosis. Expert Review of Clinical Immunology 5:1, 35-43
CrossRef131
David Iturbe Fernández, Ricardo Peris Sánchez, Alicia Ferreira Moreno, Estrella Fernández Fabrellas. (2009) Aspectos relevantes en el manejo de la enfermedad pulmonar intersticial difusa. Archivos de Bronconeumología 45, 3-8
CrossRef132
Yannick Allanore, Jérôme Avouac, André Kahan. (2008) Systemic sclerosis: an update in 2008. Joint Bone Spine 75:6, 650-655
CrossRef133
Clive Kelly, Vadivelu Saravanan. (2008) Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opinion on Pharmacotherapy 9:18, 3221-3230
CrossRef134
I. Sabnani, M. J. Zucker, E. D. Rosenstein, D. A. Baran, L. H. Arroyo, P. Tsang, M. Zubair, V. Rivera. (2008) A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology 48:1, 49-52
CrossRef135
KM Antoniou, AU Wells. (2008) Scleroderma lung disease: evolving understanding in light of newer studies. Current Opinion in Rheumatology 20:6, 686-691
CrossRef136
D. E. Furst. (2008) Outcome measures in rheumatologic clinical trials and systemic sclerosis. Rheumatology 47:Supplement 5, v29-v30
CrossRef137
J. J. F. Belch, S. McSwiggan, C. Lau. (2008) Macrovascular disease in systemic sclerosis: the tip of an iceberg?. Rheumatology 47:Supplement 5, v16-v17
CrossRef138
A. U. Wells. (2008) High-resolution computed tomography and scleroderma lung disease. Rheumatology 47:Supplement 5, v59-v61
CrossRef139
J. Behr, D. E. Furst. (2008) Pulmonary function tests. Rheumatology 47:Supplement 5, v65-v67
CrossRef140
A. U. Wells, J. Behr, R. Silver. (2008) Outcome measures in the lung. Rheumatology 47:Supplement 5, v48-v50
CrossRef141
J. R. Seibold, A. Tyndall, D. E. Furst. (2008) Trial design: how must we move ahead?. Rheumatology 47:Supplement 5, v57-v58
CrossRef142
Robert M. Elashoff, Gang Li, Ning Li. (2008) A Joint Model for Longitudinal Measurements and Survival Data in the Presence of Multiple Failure Types. Biometrics 64:3, 762-771
CrossRef143
Kamyar Afshar, Om P Sharma. (2008) Interstitial lung disease: trials and tribulations. Current Opinion in Pulmonary Medicine 14:5, 427-433
CrossRef144
David Polomis, James R Runo, Keith C Meyer. (2008) Pulmonary hypertension in interstitial lung disease. Current Opinion in Pulmonary Medicine 14:5, 462-469
CrossRef145
A. Prasse, M. Germann, J. Müller-Quernheim. (2008) Lungenbeteiligung bei Sklerodermie. Der Pneumologe 5:5, 299-307
CrossRef146
J. Hermann, G. Kovacs, S. Scheidl. (2008) Interdisziplinäre Berührungspunkte zwischen Rheumatologie und Pneumologie. Zeitschrift für Rheumatologie
CrossRef147
S. E. Elizur, R. C. Chian, C. A. Pineau, W. Y. Son, H. E. G. Holzer, J. Y. J. Huang, Y. Gidoni, D. Levin, E. Demirtas, S. L. Tan. (2008) Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology 47:10, 1506-1509
CrossRef148
Jörg H. W. Distler, Bernhard Manger, Bernd M. Spriewald, Georg Schett, Oliver Distler. (2008) Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis & Rheumatism 58:8, 2538-2542
CrossRef149
Hyun J. Kim, Gang Li, David Gjertson, Robert Elashoff, Sumit K. Shah, Robert Ochs, Fah Vasunilashorn, Fereidoun Abtin, Matthew S. Brown, Jonathan G. Goldin. (2008) Classification of Parenchymal Abnormality in Scleroderma Lung Using a Novel Approach to Denoise Images Collected via a Multicenter Study. Academic Radiology 15:8, 1004-1016
CrossRef150
E F de Carvalho, E R Parra, R de Souza, A M A’b Saber, J de Carvalho Machado, V L Capelozzi. (2008) Arterial and interstitial remodelling processes in non-specific interstitial pneumonia: systemic sclerosis versus idiopathic. Histopathology 53:2, 195-204
CrossRef151
Anil Suryaprasad, John H. Stone. (2008) When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis & Rheumatism 59:7, 1034-1039
CrossRef152
N. Hunzelmann, E. Genth, T. Krieg, M. Meurer, I. Melchers, P. Moinzadeh, C. Pfeiffer, G. Riemekasten, E. Schulze-Lohoff, C. Sunderkoetter, U. Müller-Ladner. (2008) Organspezifische Diagnostik von Patienten mit systemischer Sklerodermie. Zeitschrift für Rheumatologie 67:4, 334-340
CrossRef153
Ayumi Yoshizaki, Yohei Iwata, Kazuhiro Komura, Fumihide Ogawa, Toshihide Hara, Eiji Muroi, Motoi Takenaka, Kazuhiro Shimizu, Minoru Hasegawa, Manabu Fujimoto, Thomas F. Tedder, Shinichi Sato. (2008) CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma. The American Journal of Pathology 172:6, 1650-1663
CrossRef154
Gabriele Valentini, Marco Matucci Cerinic. (2008) Anti-inflammatory New trends in the treatment of the patient with systemic sclerosis. Expert Opinion on Emerging Drugs 13:2, 227-236
CrossRef155
Renata Villela, Sai Yan Yuen, Janet E. Pope, Murray Baron, . (2008) Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. Arthritis & Rheumatism 59:5, 706-713
CrossRef156
Nikolay P Nikolov, Steven Z Pavletic. (2008) Technology Insight: hematopoietic stem cell transplantation for systemic rheumatic disease. Nature Clinical Practice Rheumatology 4:4, 184-191
CrossRef157
H.J. Girschick. (2008) Sklerodermie im Kindes- und Jugendalter. Zeitschrift für Rheumatologie 67:2, 128-136
CrossRef158
Felix Woodhead, Athol U. Wells, Sujal R. Desai. (2008) Pulmonary Complications of Connective Tissue Diseases. Clinics in Chest Medicine 29:1, 149-164
CrossRef159
A. Taïeb, J. Constans, F.-X. Mahon. (2008) Une nouvelle piste thérapeutique pour les sclérodermies graves: le mésylate d’imatinib. La Revue de Médecine Interne 29:3, 173-175
CrossRef160
Francesco Zulian. (2008) Systemic Sclerosis and Localized Scleroderma in Childhood. Rheumatic Disease Clinics of North America 34:1, 239-255
CrossRef161
Svetlana I. Nihtyanova, Christopher P. Denton. (2008) Current Approaches to the Management of Early Active Diffuse Scleroderma Skin Disease. Rheumatic Disease Clinics of North America 34:1, 161-179
CrossRef162
J.C. Grutters, J.M.M. van den Bosch. 2008. Connective Tissue Disorders. , 713-727.
CrossRef163
John Varga, Fredrick M. Wigley. 2008. Systemic sclerosis. , 813-823.
CrossRef164
Ana C. Zamora, Paul J. Wolters, Harold R. Collard, M. Kari Connolly, Brett M. Elicker, W. Richard Webb, Talmadge E. King, Jeffrey A. Golden. (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respiratory Medicine 102:1, 150-155
CrossRef165
Jorge Rojas-Serrano, Helga Codina-Velásquez, Gabriel Medrano-Ramírez, J. Abraham Simón, Olga Vera-Lastra, Janitzia Vázquez-Mellado. (2008) Lower Incidence of Severe Damage to Target Organs in Mexican Patients With Systemic Sclerosis and Diffuse Skin Affection. Reumatolog ía Cl ínica (English Edition) 4:1, 3-7
CrossRef166
E. Hachulla. (2007) Traitement de la sclérodermie systémique (en dehors de l’hypertension artérielle pulmonaire). La Revue de Médecine Interne 28, S277-S284
CrossRef167
G. Riemekasten, D. Dragun. (2007) Risikoadaptierte Therapien bei der systemischen Sklerose. Zeitschrift für Rheumatologie 66:8, 672-678
CrossRef168
Shikha Mittoo, Fredrick M. Wigley, Robert Wise, Huiqing Xiao, Laura Hummers. (2007) Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Arthritis & Rheumatism 56:12, 4195-4202
CrossRef169
Alan Tyndall, Daniel E Furst. (2007) Adult stem cell treatment of scleroderma. Current Opinion in Rheumatology 19:6, 604-610
CrossRef170
Sheridan Henness, Fredrick M Wigley. (2007) Current drug therapy for scleroderma and secondary Raynaud??s phenomenon: evidence-based review. Current Opinion in Rheumatology 19:6, 611-618
CrossRef171
Francesco Zulian, Giorgia Martini. (2007) Childhood systemic sclerosis. Current Opinion in Rheumatology 19:6, 592-597
CrossRef172
Dinesh Khanna, Ron D. Hays, Grace S. Park, Yolanda Braun-Moscovici, Maureen D. Mayes, Terry A. McNearney, Vivien Hsu, Philip J. Clements, Daniel E. Furst. (2007) Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis & Rheumatism 57:7, 1280-1286
CrossRef173
M. Fabri, T. Krieg. (2007) Pathogenese der systemischen Sklerodermie. Der Hautarzt 58:10, 838-843
CrossRef174
Marie Hudson, Russell Steele, Murray Baron. (2007) Update on Indices of Disease Activity in Systemic Sclerosis. Seminars in Arthritis and Rheumatism 37:2, 93-98
CrossRef175
M. Meurer, P. Rehberger. (2007) Therapie bei systemischer Sklerodermie. Der Hautarzt 58:10, 851-857
CrossRef176
Norihito Yazawa, Manabu Fujimoto, Kunihiko Tamaki. (2007) Recent Advances on Pathogenesis and Therapies in Systemic Sclerosis. Clinical Reviews in Allergy & Immunology 33:1-2, 107-112
CrossRef177
V. Cottin, J.-F. Cordier. (2007) Bosentan et fibrose pulmonaire. La Revue de Médecine Interne 28, S230-S237
CrossRef178
Robert Lafyatis, Carl O'Hara, Carol A. Feghali-Bostwick, Eric Matteson. (2007) B cell infiltration in systemic sclerosis–associated interstitial lung disease. Arthritis & Rheumatism 56:9, 3167-3168
CrossRef179
Y Oyama, W G Barr, L Statkute, T Corbridge, E A Gonda, B Jovanovic, A Testori, R K Burt. (2007) Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplantation 40:6, 549-555
CrossRef180
R. A. Nash, P. A. McSweeney, L. J. Crofford, M. Abidi, C.-S. Chen, J. D. Godwin, T. A. Gooley, L. Holmberg, G. Henstorf, C. F. LeMaistre, M. D. Mayes, K. T. McDonagh, B. McLaughlin, J. A. Molitor, J. L. Nelson, H. Shulman, R. Storb, F. Viganego, M. H. Wener, J. R. Seibold, K. M. Sullivan, D. E. Furst. (2007) High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110:4, 1388-1396
CrossRef181
Allen P Anandarajah. (2007) The American College of Rheumatology Annual Scientific Meeting 2006: advances in the treatment of connective tissue diseases. Future Rheumatology 2:4, 379-384
CrossRef182
Kerill Pochetuhen, Irina G. Luzina, Virginia Lockatell, Jung Choi, Nevins W. Todd, Sergei P. Atamas. (2007) Complex Regulation of Pulmonary Inflammation and Fibrosis by CCL18. The American Journal of Pathology 171:2, 428-437
CrossRef183
Predrag Ostojic, Marco Matucci Cerinic, Richard Silver, Kristin Highland, Nemanja Damjanov. (2007) Interstitial Lung Disease in Systemic Sclerosis. Lung 185:4, 211-220
CrossRef184
Lynne Shand, Mark Lunt, Svetlana Nihtyanova, Mansour Hoseini, Alan Silman, Carol M. Black, Christopher P. Denton. (2007) Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model. Arthritis & Rheumatism 56:7, 2422-2431
CrossRef185
Irene Miniati, Marco Matucci Cerinic. (2007) Pulmonary fibrosis in systemic sclerosis: is treatment with cyclophosphamide more effective than placebo?. Nature Clinical Practice Rheumatology 3:7, 372-373
CrossRef186
Robert M. Elashoff, Gang Li, Ning Li. (2007) An approach to joint analysis of longitudinal measurements and competing risks failure time data. Statistics in Medicine 26:14, 2813-2835
CrossRef187
Nicole S. L. Goh, Srihari Veeraraghavan, Sujal R. Desai, Derek Cramer, David M. Hansell, Christopher P. Denton, Carol M. Black, Roland M. du Bois, Athol U. Wells. (2007) Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis–associated interstitial lung disease are not predictive of disease progression. Arthritis & Rheumatism 56:6, 2005-2012
CrossRef188
Joao A. de Andrade. (2007) Thoughts on the Diagnosis and Management of Interstitial Lung Diseases. Southern Medical Journal 100:6, 555-556
CrossRef189
Frank A. Wollheim, Anita ??kesson. (2007) Management of Intestinal Involvement in Systemic Sclerosis. JCR: Journal of Clinical Rheumatology 13:3, 116-118
CrossRef190
Nihal Fathi, Daniel E. Furst, Philip J. Clements. (2007) Management of interstitial lung disease in systemic sclerosis: Lessons from SLS and FAST. Current Rheumatology Reports 9:2, 144-150
CrossRef191
Dinesh Khanna, Peter A. Merkel. (2007) Outcome measures in systemic sclerosis: An update on instruments and current research. Current Rheumatology Reports 9:2, 151-157
CrossRef192
Dinesh Khanna, Xiaohong Yan, Donald P. Tashkin, Daniel E. Furst, Robert Elashoff, Michael D. Roth, Richard Silver, Charlie Strange, Marcy Bolster, James R. Seibold, David J. Riley, Vivien M. Hsu, John Varga, Dean E. Schraufnagel, Arthur Theodore, Robert Simms, Robert Wise, Fredrick Wigley, Barbara White, Virginia Steen, Charles Read, Maureen Mayes, Ed Parsley, Kamal Mubarak, M. Kari Connolly, Jeffrey Golden, Mitchell Olman, Barri Fessler, Naomi Rothfield, Mark Metersky, Philip J. Clements, . (2007) Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. Arthritis & Rheumatism 56:5, 1676-1684
CrossRef193
Manu Jain, John Varga. (2007) Mycophenolate mofetil: a promising novel therapy in systemic sclerosis. Current Rheumatology Reports 9:2, 133-135
CrossRef194
Thorsten M Olski, Nicolas Hunzelmann. (2007) Immunosuppressive and antifibrotic therapy of systemic sclerosis. Expert Review of Dermatology 2:2, 203-215
CrossRef195
Yannick Allanore, Jèrôme Avouac, Julien Wipff, André Kahan. (2007) New therapeutic strategies in the management of systemic sclerosis. Expert Opinion on Pharmacotherapy 8:5, 607-615
CrossRef196
Sabina A Antoniu. (2007) Cyclophosphamide for scleroderma interstitial lung disease. Expert Opinion on Investigational Drugs 16:3, 393-395
CrossRef197
S.Q. Hayat. (2007) Cyclophosphamide versus Placebo in Scleroderma Lung Disease. Yearbook of Medicine 2007, 33-34
CrossRef198
Frank A. Wollheim. (2007) Treatment of pulmonary fibrosis in systemic sclerosis: Light at the end of the tunnel?. Arthritis & Rheumatism 56:1, 9-12
CrossRef199
Jacob M van Laar, Jan Stolk, Alan Tyndall. (2007) Scleroderma Lung. Drugs 67:7, 985-996
CrossRef200
B.H. Thiers. (2007) Cyclophosphamide versus Placebo in Scleroderma Lung Disease. Yearbook of Dermatology and Dermatologic Surgery 2007, 200-201
CrossRef201
Lazaros I Sakkas, Ian C Chikanza, Chris D Platsoucas. (2006) Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nature Clinical Practice Rheumatology 2:12, 679-685
CrossRef202
A. Prasse, J. Müller-Quernheim. (2006) Therapie der idiopathischen interstitiellen Pneumonien. Der Internist 47:12, 1258-1262
CrossRef203
Rachel K. Hoyles, Ross W. Ellis, Jessica Wellsbury, Belinda Lees, Pauline Newlands, Nicole S. L. Goh, Christopher Roberts, Sujal Desai, Ariane L. Herrick, Neil J. McHugh, Noeleen M. Foley, Stanley B. Pearson, Paul Emery, Douglas J. Veale, Christopher P. Denton, Athol U. Wells, Carol M. Black, Roland M. du Bois. (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis & Rheumatism 54:12, 3962-3970
CrossRef204
H. Nunes. (2006) Pneumopathies interstitielles diffuses. Revue des Maladies Respiratoires 23:5, 118-128
CrossRef205
Steffan Schulz, Lindsay Bischoff, David Michel, Chris T Derk. (2006) Scleroderma lung disease: treatment with cyclophosphamide. Expert Review of Clinical Immunology 2:6, 849-852
CrossRef206
(2006) Stimulatory Autoantibodies to the PDGF Receptor in Scleroderma. New England Journal of Medicine 355:12, 1278-1280
Full Text207
(2006) Cyclophosphamide in Scleroderma Lung Disease. New England Journal of Medicine 355:11, 1173-1174
Full Text208
Lorinda Chung, Jan Lin, Daniel E. Furst, David Fiorentino. (2006) Systemic and localized scleroderma. Clinics in Dermatology 24:5, 374-392
CrossRef209
F. H. J. Hoogen. (2006) Behandlung der systemischen Sklerose. Zeitschrift für Rheumatologie 65:4, 306-310
CrossRef210
Martinez, Fernando J., McCune, W. Joseph, . (2006) Cyclophosphamide for Scleroderma Lung Disease. New England Journal of Medicine 354:25, 2707-2709
Full Text
- Letters
